Compare LCNB & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | CGEN |
|---|---|---|
| Founded | 1877 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.1M | 220.7M |
| IPO Year | N/A | 2000 |
| Metric | LCNB | CGEN |
|---|---|---|
| Price | $17.57 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 27.1K | ★ 568.8K |
| Earning Date | 01-29-2026 | 03-03-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $90,061,000.00 | $6,903,000.00 |
| Revenue This Year | $8.39 | N/A |
| Revenue Next Year | $4.07 | $164.92 |
| P/E Ratio | $10.82 | ★ N/A |
| Revenue Growth | ★ 13.66 | N/A |
| 52 Week Low | $13.34 | $1.13 |
| 52 Week High | $17.84 | $2.66 |
| Indicator | LCNB | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.78 | 43.71 |
| Support Level | $16.77 | $2.04 |
| Resistance Level | $17.75 | $2.08 |
| Average True Range (ATR) | 0.42 | 0.12 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 90.51 | 4.62 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.